2 active not recruiting, 2 completed, 1 unknown. 3 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow Radotinib: new trials by email Literature Review of Radotinib trials Research Report on Radotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Radotinib HCl 50 mg, Placebo - Parkinson Disease | Phase 2 | Active not recruiting | Il-Yang Pharm. Co., Ltd. | 43 | 2021-09-09 | 2026-09-03 |
| Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) Radotinib, Imatinib - Chronic Myeloid Leukemia, Chronic Phase | Phase 3 | Active not recruiting | Il-Yang Pharm. Co., Ltd. | 238 | 2018-12-28 | 2026-09-03 |
| Radotinib as 3rd or Later Line Therapy in CP-CML Radotinib - Chronic Myeloid Leukemia | Phase 2 | Unknown | Ulsan University Hospital | 73 | 2015-04-01 | 2016-05-11 |
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients Imatinib, Radotinib - Leukemia, Leukemia, Myeloid | Phase 3 | Completed | Il-Yang Pharm. Co., Ltd. | 242 | 2011-08-01 | 2016-02-24 |
| Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI Radotinib - Leukemia, Leukemia, Myeloid | Phase 1 / Phase 2 | Completed | Il-Yang Pharm. Co., Ltd. | 85 | 2008-07-01 | 2018-08-29 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Hematologic Diseases (2) · Leukemia (2) · Leukemia, Myeloid (2) · Leukemia, Myeloid, Chronic-Phase (2) · Philadelphia Chromosome (2) · Bone Marrow Diseases (1) · Parkinson Disease (1)
Il-Yang Pharm. Co., Ltd. (4) · Ulsan University Hospital (1)
South Korea (3) · Thailand (2) · China (1) · France (1) · India (1) · Indonesia (1) · Philippines (1)
Hawk Kim, M.D., Ph.D. (1) · IL-yang Pharm (1) · Jiang Qian (1)